N-3 полиненасыщенные жирные кислоты в фармакотерапии фибрилляции предсердий


Моисеев С.В.

Кафедра терапии и профболезней ГБОУ ВПО “Первого МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ, МГУ им. М.В. Ломоносова, Москва
В статье рассматриваются достоинства и недостатки современных методов лечения фибрилляции предсердий. Обсуждается роль n-3 полиненасыщенных жирных кислот, которые не только обладают противоаритмическими свойствами, но и оказывают благоприятное влияние на субстрат аритмии.

Литература


1. Benjamin E, Wolf P, D’Agostino R, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946–52.
2. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983–88.
3. Camm A, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Eur Heart J 2010;31(19):2369–429.
4. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667–77.
5. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003;
41:1690–96.
6. Opolski G, Torbicki A, Kosior D, et al. Rate control is rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476–86.
7. Wyse D, Waldo A, DiMarco J, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825–33.
8. Van Gelder I, Hagens V, Bosker H, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–40.
9. Hagens V, Van Veldhuisen D, Kamp O, et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005;2:19–24.
10. Brignole M, Menozzi C, Gasparini M, et al. An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation. Eur Heart J 2002;23:892–900.
11. The AFFIRM Investigators. Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004;109:1509–13.
12. Lafuente-Lafuente C, Mouly S, Long´as-Tejero M, et al. Antiarrhythmic drugs for maintaining sinus
rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719–28.
13. Connolly S, Crijns H, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebocontrolled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
Circulation 2009;120:1174–80.
14. Connolly S, Camm A, Halperin J, et al. Dronedarone in High-Risk Permanent Atrial Fibrillation. N Engl J Med 2011;365(24): 2268–76.
15. Kober L, Torp-Pedersen C, McMurray J, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678–87.
16. Van Gelder I, Haegeli L, Brandes A, et al. Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 2011;13:1517–25.
17. Saliba W, Wazni O. Sinus rhythm restoration and treatment success: insight from recent clinical
trials. Clin Cardiol 2011;34:12–22.
18. Шаваров А.А., Гончаров А.С., Глобенко А.А. и др. Фибрилляция предсердий и ассоциированные заболевания: подходы к лечению // Клин. фармакол. и тер. 2011. № 20 (5). С. 86–92.
19. Maggioni A, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence:ancillary results of the GISSI-HF trial. Eur Heart J2009;19:2327–36.
20. Pederson O, Bagger H, Kober L, et al, for the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation
1999;100:376–80.
21. Vermes E, Tardif J, Bourassa M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction. Сirculation 2003;107:2926–31.
22. Ducharme A, Swedberg K, Pfeffer M, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86–92.
23. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712–19.
24. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007;99:1544–48.
25. Disertori M, Zeni P, Quintarelli S, Bonmassari R. Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation. G Ital Cardiol 2010;11:829–34.
26. ACTIVE I Investigators, Yusuf S, Healey J, Pogue J, et al. Irbesartan in patients with atrial fibrillation.
N Engl J Med 2011;364(10):928–38.
27. Ramadeen A, Laurent G, dos Santos C, et al. n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm 2010;7(4):520–28.
28. Laurent G, Moe G, Hu X, et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc Res 2008;77:89–97.
29. Lau D, Psaltis P, Carbone A, et al. Atrial protective effects of n-3 polyunsaturated fatty acids: a longterm
study in ovine chronic heart failure. Heart Rhythm 2011;8(4):575–82.
30. Savelieva I, Kourliouros A, Camm J. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn-Schmied Arch Pharmacol 2010;381:207–19.
31. Leaf A, Kang J, Xiao Y, Billman G. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646–52.
32. Calder P. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006;83:1505S–19S.
33. Ninio D, Murphy K, Howe P, Saint D. Dietary fish oil protects against stretch-induced vulnerability to atrial fibrillation in a rabbit model. J Cardiovasc Electrophysiol 2005;16:1189–94.
34. Li G, Sun H, Zhang X, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+currents and Na+ current in human atrial myocytes. Cardiovasc Res 2009;81:286–93.
35. Boland L, Drzewiecki M. Polyunsaturated fatty acid modulation of voltage-gated ion channels. Cell Biochem Biophys 2008;52:59–84.
36. Xiao Y, Ke Q, Chen Y, et al. Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004;321:116–23.
37. Sarrazin J, Comeau G, Daleau P, et al. Reduced incidence of vagally induced atrial fibrillation and expression levels of connexins by n-3 polyunsaturated fatty acids in dogs. J Am Coll Cardiol 2007;50(15):1505–12.
38. Kumar S, Sutherland F, Rosso R, et al. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology. Heart Rhythm 2011;8(4):562–68.
39. Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы // Кардиология 2010. № 8. С. 47–53.
40. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723–28.
41. Панов А.В., Татарский Б.А., Гордеев М.Л., Нильк Р.Я. Омега-3-полиненасыщенные жирные кислоты в профилактике фибрилляции предсердий после хирургической реваскуляризации миокарда // Рациональная фармакотерапия в кардиологии 2008. № 3. С. 26–30.
42. Mozaffarian D, Psaty B, Rimm E, et al. Fish intake and risk of incident atrial fibrillation. Circulation
2004;110:368–73.
43. Virtanen J, Murus J, Voutilainen S, Tuomainen T. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009;120: 2315–21.
44. Berry J, Passman R, Prineas R, et al. Fish and omega-3 fatty acid intake and incident atrial fibrillation: the Women’s Health Initiative. Heart Rhythm 2008;5:S22 (Abstract).
45. Brouwer I, Heeringa J, Geleijnse J, et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam study. Am Heart J 2006;151:857–62.
46. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish diet, cancer, and health study. Am J Clin Nutr 2005;81:50–54.
47. Nodari S, Triggiani M, Campia U, et al. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective randomized study. Circulation 2011;124:11.
48. Bianconi L, Calo L, Mennuni M, et al. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, doubleblind,
multicentre study. Europace 2011;13(2):174–81.
49. Kowey P, Reiffel J, Ellenbogen K, et al. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 2010;304:2363–72.
50. Camm J, Savelieva I. Fish oil for secondary prevention of atrial fibrillation should we still believe in its antiarrhythmic effect? Circulation 2011;124:1093–109.
51. Macchia A, Varini S, Grancelli H, et al. The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebocontrolled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J 2009;157(3):423–27.
52. Savelieva I, Kakouros N, Kourliouros A, Camm A. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011;13:610–25.
53. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infraction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55.
54. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1223–130.


Об авторах / Для корреспонденции


Моисеев Сергей Валентинович – доктор медицинских наук, профессор кафедры терапии и профболезней ГБОУ ВПО “Первого МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ, МГУ им. М.В. Ломоносова. Е-mail: clinpharm@mtu-net.ru


Похожие статьи


Бионика Медиа